A 65% collapse from its October 2025 peak has left IonQ (NASDAQ: IONQ) trading near $30, a level that some analysts now view as a compelling entry point for risk-tolerant investors.
The quantum computing firm sits well below its former all-time high above $80 per share, yet the business itself has continued to grow throughout the downturn, making the valuation gap harder to ignore.
IonQ’s decline mirrors a broader pattern among speculative technology names, where investor risk appetite, rather than underlying fundamentals, tends to drive the stock’s daily direction.
That dynamic cuts both ways, and a meaningful shift in sentiment tied to a concrete commercial catalyst could close the distance to those prior highs relatively quickly.
The catalyst most closely watched is IonQ’s planned launch of a 256-qubit quantum computer in early 2027, a product the company has already secured several preorders for ahead of its release.
Achieving that milestone would firmly establish IonQ as one of the leading commercial players in a field where large-scale, reliable quantum hardware remains elusive for most competitors.
The company’s technology has already reached 99.99% fidelity, a benchmark that signals meaningful progress toward the kind of precision enterprises and government customers would require before committing to large contracts.
Despite still operating at a start-up stage, IonQ is generating what observers describe as sizable revenue figures, distinguishing it from many quantum computing peers that remain purely pre-revenue research operations.
The stock is still considered expensive on conventional valuation metrics, though it trades at a notable discount relative to where it stood when investor enthusiasm for quantum computing was at its height.
A successful 256-qubit launch could reignite that enthusiasm, with some projections placing the stock back above $80 per share by the close of 2027, a gain of more than 100% from current trading levels.
The path there is not without risk, as any delay or technical shortfall in the 2027 product timeline could extend the stock’s period of underperformance and test the patience of investors who buy in at today’s prices.
For those with a higher tolerance for speculative exposure, however, the combination of a defined near-term product launch, existing preorder demand, and a stock price less than half its previous high presents a risk-reward profile that is difficult to dismiss outright.
